Intercept Pharmaceuticals (ICPT) is developing a first-in-class drug, obeticholic acid (OCA) that modulates bile production to reduce liver stress. Because OCA is a first-in-class drug targeting an orphan disease known as primary biliary cirrhosis (PBC) and appears to be safe and effective, OCA has a high probability of FDA approval. The long-term strategy of ICPT is promising: Piggybacking on the natural properties and bioactivity of bile acids will open doors for ICPT in large chronic disease markets that include metabolic disorders (diabetes/obesity) and heart disease. ICPT's market cap ($1B) is on par with other companies in a similar situation. I am waiting to see the Phase III clinical trial results this quarter and early in 2014 before...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: